Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Location status: Recruiting
NCT Number: NCT01246765
The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.
Interested in participating?
Request Info18 year–45 year
Female
Observational
Boston, Massachusetts, 02114, United States
Location status: Recruiting
The overarching objectives of the National Pregnancy Registry for Psychiatric Medications are twofold: to assess risk for malformations among infants exposed to specific psychiatric medications and to assess neonatal outcomes associated with prenatal exposure to such medication. Specifically, the Registry will allow us to prospectively determine whether exposure to psychiatric medication is associated with any increased risk for major malformations above the baseline risk noted in the general population. This will be achieved by careful systematic documentation of medication exposure during pregnancy, as well as other relevant exposures often not included in small case series or published reviews of drug safety derived from large administrative databases.
Although psychiatric medications are widely used by reproductive age women, reliable data regarding the reproductive safety of many of these compounds is limited. As a result, clinicians often lack sufficient evidence to evaluate the risks and benefits of using medications to treat psychiatric disorders during pregnancy. The National Pregnancy Registry for Psychiatric Medications is one of the first, and largest, hospital-based pregnancy registries which will systematically and prospectively monitor pregnancy outcomes after exposure to psychiatric medications, including antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics.
Primary Aim:
To prospectively evaluate rates of congenital malformations among infants exposed in-utero to psychiatric medications.
Secondary Aims:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Birth up to 1 year; assessed at 8-12 weeks postpartum, assessed through medical records through 1 year of age.
The primary outcome for this study is rates of major malformations among infants exposed in-utero to psychiatric medications. A major malformation is defined as a structural abnormality with surgical, medical, or cosmetic importance. Exclusions include (1) minor anomalies; (2) deformations; (3) physiologic features due to prematurity, such as undescended testes; (4) birthmarks; (5) genetic disorders and chromosomal abnormalities; and (6) any finding by prenatal sonography, such as absence of 1 kidney, or at surgery (or autopsy) that was not identified by an examining pediatrician. This data is collected through review of pediatric medical records through the first twelve months of infants' lives.
Time frame: Change from pre-pregnancy to delivery; assessed at 7 months' gestation and 8-12 weeks postpartum.
Maternal gestational weight gain is measured by the change in maternal weight from pre-pregnancy to weight at delivery, recorded in pounds.
Time frame: Birth; assessed at 8-12 weeks postpartum.
Did the pregnancy end in a live birth, assessed as a yes/no outcome.
Time frame: Any time during pregnancy; assessed at 7 months' gestation and 8-12 weeks postpartum.
Did a spontaneous abortion (SAB) occur during the pregnancy, assessed as a yes/no outcome.
Time frame: Any time during pregnancy; assessed at 7 months' gestation and 8-12 weeks postpartum.
Did intrauterine fetal demise (IUFD) occur during the pregnancy, assessed as a yes/no outcome.
Time frame: Birth; assessed at 8-12 weeks postpartum.
The gestational age of the infant at birth, recorded in weeks and days.
Time frame: Any time during pregnancy; assessed at 7 months' gestation and 8-12 weeks postpartum.
Was the baby born before 37 weeks gestational age, assessed as a yes/no outcome.
Time frame: Birth; assessed at 8-12 weeks postpartum.
Birth weight of the infant, recorded in grams or lbs and oz
Time frame: Birth; assessed at 8-12 weeks postpartum.
Was birth vaginal or by C-section; if C-section, emergent: yes/no
Time frame: Any time during pregnancy; assessed at baseline, 7 months' gestation and 8-12 weeks postpartum.
Gestational diabetes diagnosed during pregnancy, assessed as a yes/no outcome.
Time frame: Any time during pregnancy; assessed at baseline, 7 months' gestation and 8-12 weeks postpartum.
Gestational hypertension diagnosed during pregnancy, assessed as a yes/no outcome.
Time frame: Any time during pregnancy; assessed at baseline, 7 months' gestation and 8-12 weeks postpartum.
Pre-eclampsia or eclampsia diagnosed during pregnancy, assessed as a yes/no outcome.
Time frame: Birth; assessed at 8-12 weeks postpartum.
Did maternal postpartum hemorrhage occur, assessed as a yes/no outcome.
Time frame: Birth; assessed at 8-12 weeks postpartum.
1-min and 5-min Apgar scores.
Time frame: Birth up to 1 year; assessed at 8-12 weeks postpartum, assessed through medical records through 1 year of age.
Was the infant admitted to the NICU, assessed as a yes/no outcome; if yes, number of days in NICU and reason for admission
Time frame: Birth up to 1 year; assessed at 8-12 weeks postpartum, assessed through medical records through 1 year of age.
Did the infant die before the age of one; assessed as a yes/no outcome.
Time frame: Birth through 1 year; assessed at 8-12 weeks postpartum, assessed through medical records through 1 year of age.
Did movement dysfunction occur in the infant (such as dystonia, akathisia, parkinsonism characteristic symptoms such as rigidity, bradykinesia, tremor, and tardive dyskinesia); assessed as a yes/no outcome.
Time frame: Birth through 1 year; assessed at 8-12 weeks postpartum, assessed through medical records through 1 year of age.
Did poor neonatal adaptation syndrome (PNAS) occur (including poor muscle tone, tremors, jitteriness, irritability, seizures, feeding difficulties, sleep disturbances, hypoglycemia, and respiratory distress); assessed as a yes/no outcome
Time frame: Assessed at 9 months, year 3, and year 5.
Were there developmental concerns, as assessed by the Ages and Stages Questionnaire (ASQ-3).
Time frame: Assessed at 9 months, year 3, and year 5.
Were there developmental concerns, as assessed by the Preschool Child Behavior Checklist (CBCL).
Time frame: Assessed at 8-12 weeks postpartum.
Did breastfeeding occur, assessed as a yes/no outcome; if yes, duration of breastfeeding recorded in weeks.
Contact information is provided by the study sponsor or research team.
Bryn Rediger
CONTACT
Lee Cohen, MD
CONTACT
Massachusetts General Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07413393
Intervention, Knowledge
Valencia, Spain
View Trial DetailsNCT04964206
Agnosia, Analgesia, Epidural
Beijing, Beijing Municipality, China
View Trial DetailsNCT06575309
Pregnant Women, Venous Thromboembolic Disease
Clermont-Ferrand, France
View Trial DetailsNCT05358834
Pregnant Women
Boston, Massachusetts, United States
View Trial Details